List of Excipients in Branded Drug EPIFOAM

Generic Drugs Containing EPIFOAM

Company	Ingredient	NDC	Excipient
Viatris Specialty LLC	pramoxine hydrochloride and hydrocortisone acetate	0037-6824	CETYL ALCOHOL
Viatris Specialty LLC	pramoxine hydrochloride and hydrocortisone acetate	0037-6824	GLYCERYL MONOSTEARATE
Viatris Specialty LLC	pramoxine hydrochloride and hydrocortisone acetate	0037-6824	ISOBUTANE
Viatris Specialty LLC	pramoxine hydrochloride and hydrocortisone acetate	0037-6824	LAURETH-23
Viatris Specialty LLC	pramoxine hydrochloride and hydrocortisone acetate	0037-6824	METHYLPARABEN
Viatris Specialty LLC	pramoxine hydrochloride and hydrocortisone acetate	0037-6824	PEG-100 STEARATE

What are the Most Frequently-Used Excipients in EPIFOAM?

# Of NDCs	Excipient
1	CETYL ALCOHOL
1	GLYCERYL MONOSTEARATE
1	ISOBUTANE
1	LAURETH-23
1	METHYLPARABEN
1	PEG-100 STEARATE

Epifoam Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Epifoam is a prescription rectal aerosol foam combining hydrocortisone acetate, a topical corticosteroid, with pramoxine hydrochloride, a local anesthetic. Its commercial value is driven by delivery performance, patient tolerability, and product convenience rather than by novel active-ingredient protection. The strongest opportunities are a differentiated generic, a lower-irritancy reformulation, improved packaging, and potential expansion into adjacent anorectal indications.

What is Epifoam and how does the product work?

Epifoam contains hydrocortisone acetate 1% and pramoxine hydrochloride 1%. The product is used for temporary relief of itching, burning, and discomfort associated with hemorrhoids and other inflammatory anorectal conditions. Hydrocortisone reduces inflammation, while pramoxine provides local anesthetic activity.[1]

Epifoam product profile

Attribute	Epifoam profile
Active ingredients	Hydrocortisone acetate 1%; pramoxine hydrochloride 1%
Dosage form	Topical rectal aerosol foam
Route	Anorectal application
Therapeutic category	Corticosteroid plus local anesthetic
Primary use	Hemorrhoidal symptoms and inflammatory anorectal disorders
Regulatory pathway	Prescription drug product
Biologic risk	None
Primary competitive alternatives	Creams, ointments, suppositories, wipes, nonprescription hydrocortisone products
Main formulation challenge	Producing a stable, low-irritancy foam that spreads across sensitive tissue

The foam dosage form can provide a practical advantage over ointments and suppositories. It is easier to spread, may reduce the need for mechanical insertion, and can improve coverage of external and perianal tissue. Those benefits depend on foam collapse, dose consistency, applicator design, and patient perception.

What excipients are important in an Epifoam formulation?

The excipient system must balance foam generation, emulsion stability, preservative protection, skin tolerability, and compatibility with the aerosol container. A successful formulation cannot optimize only viscosity or foam height. It must preserve drug content and deliver a reproducible dose throughout the product’s shelf life.

Functional excipient categories

Excipient function	Strategic objective	Key development issue
Aqueous vehicle	Dissolve or disperse hydrophilic components	pH, microbial control, drug stability
Emollient phase	Reduce dryness and improve spreadability	Greasiness and residue
Fatty alcohol or wax system	Build foam structure and emulsion body	Excessive stiffness or poor discharge
Surfactant	Stabilize the emulsion and improve wetting	Irritation and active-ingredient compatibility
Humectant	Reduce tissue dryness	Osmolality and tackiness
Preservative	Protect a multidose aqueous product	Sensitization and regulatory acceptability
Propellant	Generate and expel foam	Flammability, pressure, valve performance
Chelating agent or buffer	Control oxidation and pH drift	Compatibility with actives and packaging
Antioxidant	Protect susceptible ingredients or excipients	Sensory effects and extractables risk

Public labeling identifies conventional emulsion and aerosol excipient classes for Epifoam, including fatty alcohols, surfactant components, glycols, water, and preservative-related ingredients.[1] The exact commercial composition should be treated as formulation-specific and controlled through the current FDA-approved labeling and manufacturing records.

The highest-value excipient decisions

Foam structure and collapse

Rectal foam products require a narrow performance range. Foam that collapses too quickly may reduce consumer confidence and coverage. Foam that remains too persistent can be difficult to distribute and may increase residue.

A differentiated generic could target controlled collapse after application. The product should discharge as a coherent foam, spread with low shear, and then partially collapse to form a thin medicated film. This design could improve coverage without creating an overly occlusive or greasy sensation.

Surfactant and preservative tolerability

The perianal region is vulnerable to irritation, especially in patients with fissures, dermatitis, inflammation, or damaged mucosa. Surfactants and preservatives can create a commercial disadvantage if they produce stinging or contact sensitization.

A reformulation opportunity exists around:

• Lower-irritancy surfactant systems
• Reduced preservative burden
• Preservative-free packaging, if microbiological protection is demonstrated
• Alternative preservative systems with better tolerability data
• Lower residual fragrance or odor, including a fragrance-free positioning

Any excipient substitution must preserve product performance and avoid creating a new safety or equivalence burden.

Humectants and emollients

Propylene glycol and related glycols can improve solubilization and moisture retention, but they can sting compromised tissue. Alternative humectant systems may support a gentler product profile, although increased viscosity or tack can impair foam discharge.

A useful development target is a low-residue emulsion that reduces tissue drying without creating the persistent oily film associated with some ointments.

pH and osmolality

The formulation should minimize stinging while maintaining chemical stability and preservative effectiveness. The pH must support both active ingredients and the selected preservative system. Excessively acidic or alkaline formulations can reduce patient acceptance and increase local discomfort.

For a follow-on product, pH and osmolality should be controlled within a range demonstrated to support equivalent performance and local tolerability. A reformulated product may require additional clinical or bridging data if the excipient changes materially affect exposure or tissue response.

What formulation patents protect Epifoam?

Epifoam’s commercial protection is unlikely to depend on a modern, long-duration active-ingredient patent estate. Hydrocortisone acetate and pramoxine hydrochloride are established small-molecule ingredients, and the product has been marketed for many years. The principal barriers are likely regulatory, manufacturing, device, and market-access barriers rather than basic composition-of-matter rights.

Patent and exclusivity assessment

Protection category	Strategic assessment
Hydrocortisone acetate composition patent	No meaningful current blocking position expected
Pramoxine hydrochloride composition patent	No meaningful current blocking position expected
Combination patent	Any relevant rights would likely be old or narrow
Foam formulation patents	Possible historical or improvement patents; current enforceability requires claim-level review
Applicator or valve patents	Potentially relevant to a differentiated device presentation
Manufacturing patents	Possible process protection for emulsion, filling, or foam generation
FDA exclusivity	No biologic exclusivity; any remaining product-specific exclusivity would need confirmation in FDA records
Orange Book patent risk	Expected to be limited relative to newer complex topical products

The FDA Orange Book is the controlling source for current listed patents and regulatory exclusivity associated with an approved product.[2] A commercial program should not assume that an old product has no enforceable rights without checking the current listing, patent family, terminal disclaimers, and litigation history.

When does Epifoam lose exclusivity and what generic entry risks exist?

Epifoam is not exposed to biosimilar competition because it is a small-molecule drug. Its competitive risk comes from generic or therapeutically substitutable topical products.

A generic applicant may pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. Aerosol foam products are more complex than conventional creams because equivalence may depend on:

• Active-ingredient strength
• Qualitative and quantitative excipient composition
• Foam density
• Discharge rate
• Particle or droplet characteristics
• Spray pattern and plume geometry
• Valve and actuator performance
• Product texture and collapse time
• Drug distribution within the discharged foam
• Container pressure and fill weight
• Microbiological quality and preservative effectiveness

The FDA’s guidance for topical dermatological products recognizes that local products may require multiple comparative performance tests, especially where systemic pharmacokinetic studies are not sufficiently sensitive.[3]

ANDA versus 505(b)(2) strategy

Development route	Best use case	Commercial benefit	Main risk
ANDA	Same active ingredients, strength, dosage form, and reference design	Lower clinical burden and direct generic substitution	Tight equivalence requirements
505(b)(2) NDA	New excipients, new device, modified foam, or broader indication	Differentiated labeling and potential product claims	Higher development cost and clinical requirements
OTC switch or monograph route	Consumer hemorrhoid positioning	Larger retail access	Labeling, monograph, and active-ingredient constraints
Co-development or licensing	Existing foam technology combined with Epifoam actives	Faster technical entry	Royalty and control obligations

An ANDA is likely to be the most efficient route for a close generic. A 505(b)(2) strategy becomes more attractive when the product has a demonstrable advantage, such as reduced irritation, preservative-free delivery, improved applicator ergonomics, or a new indication.

What commercial opportunities exist for Epifoam excipient innovation?

1. A low-irritancy generic foam

The most direct opportunity is a generic product that matches Epifoam’s therapeutic profile but improves local tolerability. Positioning could focus on fragrance-free use, reduced sting, lower residue, and a smoother foam.

The product would compete against both branded Epifoam and lower-cost hydrocortisone creams. Its value proposition would depend on patient experience, not simply price.

2. A preservative-reduced or preservative-free presentation

A multidose aqueous foam creates microbiological challenges. A preservative-free presentation could use a barrier container, metered-dose valve, bag-on-valve system, or other packaging architecture that limits product exposure to air and contamination.

This opportunity has two commercial advantages:

• It can support a sensitive-skin or sensitive-tissue positioning.
• It can create device and packaging differentiation that is harder to copy than a simple excipient substitution.

The tradeoff is higher packaging cost and a more demanding extractables, leachables, microbial, and stability program.

3. A patient-friendly applicator

The applicator is commercially important in rectal products. A narrow, smooth, disposable or cleanable applicator can reduce discomfort and improve dose placement. A short external-use actuator may support treatment of perianal symptoms without requiring deep insertion.

Device improvements could support:

• Reduced insertion force
• Lower contamination risk
• More consistent delivered dose
• Improved handling for older patients
• Better compatibility with travel and home use

A device-led product may qualify for separate patent protection if the design is technically distinctive.

4. A lower-residue foam

Patients often discontinue topical anorectal products because of greasiness, leakage, staining, or difficult cleanup. A foam that leaves a thin film instead of an oily residue could compete effectively against ointments and suppositories.

The formulation target is a stable emulsion with rapid spread, controlled collapse, low tack, and sufficient occlusivity to prevent tissue drying.

5. Combination-product lifecycle expansion

A company could evaluate variants using the same delivery platform for:

• Hydrocortisone-only foam
• Pramoxine-only foam
• Barrier-supportive foam
• Antifungal or antibacterial combinations where medically justified
• Pediatric or geriatric presentations with revised applicator geometry

Each variant would require a separate regulatory and medical assessment. Combination expansion can increase manufacturing complexity and may dilute the core product if the indications are not clearly differentiated.

What is the FDA regulatory status and Orange Book position?

Epifoam is an FDA-approved prescription topical foam product. Its active ingredients are established, but the dosage form creates product-specific quality and equivalence requirements. The FDA-approved label controls the indicated population, route, warnings, dosing, storage, and inactive-ingredient disclosure.[1]

The Orange Book should be used to confirm:

• Reference listed drug status
• Any listed patents
• Pediatric exclusivity
• Regulatory exclusivity
• Approved applicants and dosage-form details
• Whether the product remains actively marketed

For an ANDA applicant, the key regulatory question is not whether the active ingredients are old. It is whether the proposed foam can demonstrate pharmaceutical equivalence and bioequivalence through an acceptable combination of comparative physicochemical, performance, microbiological, and, where necessary, clinical testing.

Which companies are challenging Epifoam and what is the competitive landscape?

Competition comes from four groups rather than a single direct rival.

Competitor group	Examples of products or strategies	Competitive pressure
Generic hydrocortisone products	Creams, ointments, suppositories	Low price and broad pharmacy availability
Pramoxine products	Creams, lotions, wipes	Anesthetic-focused symptom relief
Combination anorectal products	Steroid, anesthetic, astringent, or protectant combinations	Brand recognition and retail presence
Non-drug alternatives	Barrier creams, wipes, sitz baths, procedural care	Substitution for mild symptoms

Epifoam’s strongest differentiation is its combination of anti-inflammatory and anesthetic activity in a foam. Its weakness is likely limited market size, prescription friction, and the availability of lower-cost creams and over-the-counter hemorrhoid products.

How strong is the Epifoam patent estate?

The patent estate appears commercially modest relative to newer dermatology and specialty products. The strongest defensible positions are more likely to arise from:

1. A proprietary foam architecture.
2. A novel container or valve system.
3. A low-irritancy preservative package.
4. A reproducible drug-distribution manufacturing process.
5. A specialized applicator.
6. New clinical labeling supported by a 505(b)(2) program.

A basic substitution of one conventional excipient for another is unlikely to create durable freedom-to-operate protection. Patent value increases when the formulation change produces measurable technical effects, such as improved stability, reduced irritation, more consistent dose delivery, or superior foam performance.

What licensing deals could create value?

Licensing opportunities are most credible in platform technologies rather than in the Epifoam brand itself. Potential partners include:

• Aerosol foam manufacturers
• Bag-on-valve packaging suppliers
• Specialty dermatology companies
• Generic pharmaceutical companies with topical development capabilities
• Contract development and manufacturing organizations
• Companies with established pharmacy distribution in anorectal products

A licensing transaction could take the form of an ingredient-and-device package, a territory-specific commercialization agreement, or a co-development program for a reformulated foam. The most valuable deal structure would link royalties to differentiated claims or a protected device, rather than to an undifferentiated generic.

What manufacturing and intellectual-property barriers affect Epifoam?

Manufacturing is a meaningful barrier because the product combines a semisolid emulsion with aerosol or foam delivery. Critical process variables include:

• Active-ingredient dispersion
• Emulsion particle-size distribution
• Heating and cooling profile
• Homogenization energy
• Fill weight
• Propellant charge
• Valve crimping
• Container pressure
• Microbial control
• Stability under temperature cycling

Scale-up can change foam texture even when the nominal formula is unchanged. A manufacturer with validated filling equipment, aerosol experience, and in-house analytical methods may have an advantage over a company that only owns a topical formulation.

The most defensible manufacturing know-how may remain a trade secret rather than a patent. Process patents should be evaluated for claim breadth, expiration, geographic coverage, and whether a non-infringing process is practical.

Key Takeaways

• Epifoam combines hydrocortisone acetate 1% and pramoxine hydrochloride 1% in a prescription rectal aerosol foam.
• The product’s commercial differentiation comes from delivery format and patient experience, not novel active ingredients.
• The strongest excipient opportunities are low-irritancy surfactant systems, lower-residue emulsions, improved preservative strategies, and better applicators.
• A close generic would likely pursue an ANDA, while a differentiated foam or device could support a 505(b)(2) strategy.
• Foam density, collapse time, valve performance, dose uniformity, microbial protection, and packaging compatibility are central development risks.
• Biosimilar competition is irrelevant. Generic and therapeutic substitution are the principal market threats.
• The patent estate is likely modest unless protected by a specific foam, device, manufacturing, or labeling improvement.
• A commercially attractive program should target a clear patient benefit, not a nominal excipient change.

FAQs

Is Epifoam a steroid or a local anesthetic?

It is both. Hydrocortisone acetate is the corticosteroid, and pramoxine hydrochloride is the local anesthetic.

Can Epifoam be reformulated with different preservatives?

Potentially, but the reformulated product must maintain stability, microbial protection, active-ingredient compatibility, and acceptable local tolerability. The regulatory pathway depends on the scope of the change.

Is an Epifoam generic difficult to develop?

Yes. The active ingredients are established, but aerosol foam equivalence involves formulation, valve, container, discharge, foam, and dose-delivery performance.

Could a preservative-free Epifoam product be commercially viable?

Yes, if packaging can control contamination and the product retains acceptable stability and usability. The opportunity is strongest in sensitive-tissue and low-irritancy positioning.

Does Epifoam have biosimilar risk?

No. Epifoam is a small-molecule topical drug. Its principal competitive risks are generic entry, alternative topical dosage forms, and nonprescription hemorrhoid products.

References

1. U.S. Food and Drug Administration. (n.d.). Epifoam hydrocortisone acetate and pramoxine hydrochloride aerosol, foam: Prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Topical dermatological drug products submitted for abbreviated new drug applications. FDA.